Corcept Therapeutics Incorporated has announced that it will present new data from its pivotal Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The study focuses on the use of relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer who were previously treated with a PARP inhibitor. This patient population is noted for having a particularly poor prognosis. The data will be shared during a late-breaking mini oral session on October 19, 2025. The ROSELLA trial is being conducted in collaboration with several international oncology groups, including The GOG Foundation, Inc., ENGOT, APGOT, LACOG, and ANZGOG.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922541539) on September 22, 2025, and is solely responsible for the information contained therein.